<DOC>
	<DOCNO>NCT01096199</DOCNO>
	<brief_summary>Hypothesis : The addition RAD001 TS-1/CDDP safe improve efficacy TS-1/CDDP . The rationale combining RAD001 TS-1/CDDP : 1 . Potential synergism combination TS-1/CDDP Activation PI3K/AKT/mTOR pathway frequently characteristic worsening prognosis ( increased aggressiveness ) , resistance treatment , extension disease progression . The antitumour effect RAD001 mediate antiproliferative antiangiogenic activity mTOR inhibition . In preclinical study , RAD001 demonstrate synergism CDDP several cancer type include lung ( A549 ; CI 0.47 ) , epidermoid cancer ( KB-31 ; CI 0.74 ) , colon cancer ( HCT116 ; CI 0.47 ) gastric cancer ( SNU 1 ; CI 0.204 , SNU 216 ; CI 0.546 , SNU 638 ; CI 0.039 , SNU 668 ; CI 0.396 ) ( IB , Lee 2008 AACR ) . 2 . Potential overcome TS-1/CDDP resistance . Upregulation Akt pathway find important mechanism acquire resistance CDDP ( Lee 2005 Gyn Onc , Liu 2007 Cancer Res ) . In addition , gastric cancer upregulated Akt pathway associate primary resistance 5- fluorouracil , adriamycin , mitomycin C , cisplatin ( Oki 2007 PASCO ) 3 . Overlapping antitumour activity TS-1/CDDP RAD001 effective well tolerated subcutaneous tumour establish variety tumour cell line diverse histotypes ( NSCLC , pancreatic , gastric , colon , renal , melanoma , epidermoid ) , include Pgp170-overexpressing , multi-drug resistant tumor line . Partial response single agent RAD001 see patient gastric cancer dose 5mg/day 2 patient ( gastric oesophageal cancer ) dose 10mg/day , study C2101 C1101 respectively . A clinical benefit ( stable disease , partial response complete response ) observe 55 % patient gastric cancer fail 1st line therapy ( Yamada 2009 GCS ASCO ) . A phase III study RAD001 patient 2nd/3rd line gastric cancer currently open recruitment .</brief_summary>
	<brief_title>A Study TS-1 , Cisplatin ( CDDP ) RAD001 ( Everolimus )</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically document locally advanced , metastatic recurrent solid malignancy refractory standard therapy , convention therapy effective platinum/fluoropyrimidine indicate . At least one measurable evaluable disease define RECIST Age &gt; 21 year old Performance status ( ECOG ) 02 Life expectancy &gt; 3 month No significant problem oral intake drug administration Adequate organ function : bone marrow function ( ANC ≥ 1,500/uL , Platelet ≥ 100,000/ uL , Hb ≥ 9.0 g/dl ) renal function : serum creatinine ≤ UNL ( serum creatinine &gt; ULN , creatinine clearance ≥ 60 mL/min ) hepatic function ( Total bilirubin &lt; 2 x UNL AST/ALT level &lt; 3 x ULN without liver metastasis , total bilirubin &lt; 3x ULN AST/ALT level &lt; 5 x ULN liver metastasis ) Prior systemic therapy ( eg , cytotoxic chemotherapy biologic therapy ) major surgery allow least 28 day elapse completion therapy administration study drug Ability understand willingness sign write informed consent study entry Failure recover reversible effect previous chemotherapy , radiotherapy , hormonal , biologic therapy prior enrollment Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) Prior radiotherapy administer target lesion select study , radiotherapy nontarget lesion complete within 4 week randomization Prior mTOR inhibitor Presence symptomatic progressing CNS metastasis Serious illness medical condition : Congestive heart failure ( NYHA class III IV ) , unstable angina myocardial infarction within past 12 month Significant arrhythmias require medication conduction abnormality 2nd degree AV block Uncontrolled hypertension Hepatic cirrhosis ( ≥ Child class B ) Interstitial pneumonia Psychiatric disorder may interfere protocol compliance Unstable diabetes mellitus Uncontrolled ascites pleural effusion Active infection Receiving concomitant treatment interact TS1 , cisplatin RAD001 . Flucytosine ( fluorinated pyrimidine antifungal agent ) Antivirals sorivudine , ramivudine , brivudine chemically related agent , warfarin , phenprocoumon , phenytoin , allopurinol , immunosuppressive agent . Strong moderate inhibitor inducer Pglycoprotein , CYP3A4 CYP3A5 ( appendix A ) eligible ; minimal 2 week wash period require stop medication Known hypersensitivity TS1 , CDDP mTOR inhibitor . Pregnant lactate woman . Women child bear potential use contraceptive method Sexually active fertile men use effective birth control medication study drug 6 month completion study drug partner woman childbearing potential Any patient judge investigator unfit participate study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>The purpose study evaluate safety feasibility combine TS-1/CDDP RAD001 . Primary</keyword>
	<keyword>Objectives</keyword>
	<keyword>To determine MTD/recommended phase II dose TS-1/CDDP/RAD001 combination —To determine</keyword>
	<keyword>safety TS-1/CDDP/RAD001 combination Secondary Objectives —To preliminarily describe clinical activity</keyword>
	<keyword>platinum refractory disease</keyword>
	<keyword>To assess effect concurrent TS-1/CDDP RAD001 pharmacokinetics —To explore</keyword>
	<keyword>relationship tumour biomarkers treatment response</keyword>
</DOC>